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Abstract  
Background: PD-L1 on tumour cells suppresses host immunity through binding to its 
receptor PD-1 on lymphocytes, and promotes peritoneal dissemination in mouse models 
of ovarian cancer. However, how PD-L1 expression is regulated in ovarian cancer 
microenvironment remains unclear.  
Methods: Number of CD8-positive lymphocytes and PD-L1 expression in tumour cells 
was assessed in ovarian cancer clinical samples. PD-L1 expression and tumour 
progression in mouse models under conditions of altering IFN-γ signals was assessed. 
Results: The number of CD8-positive cells in cancer stroma was very high in 
peritoneally disseminated tumours, and was strongly correlated to PD-L1 expression on 
the tumour cells (P<0.001). In mouse models, depleting IFNGR1 resulted in lower level 
of PD-L1 expression in tumour cells, increased number of tumour-infiltrating 
CD8-positive lymphocytes, inhibition of peritoneal disseminated tumour growth, and 
longer survival (P=0.02). The injection of IFN-γ into subcutaneous tumours induced 
PD-L1 expression and promoted tumour growth, and PD-L1 depletion completely 
abrogated tumour growth caused by IFN-γ injection (P=0.01).  
Conclusion:  IFN-γ secreted by CD8-positive lymphocytes up-regulates PD-L1 on 
ovarian cancer cells and promotes tumour growth. The lymphocyte infiltration and the 
3 
IFN-γ status may be the key to effective anti-PD-1 or anti-PD-L1 therapy in ovarian 
cancer. 
 




Ovarian cancer is the most lethal disease among the gynaecological malignancies. 
Most cases present massive peritoneal dissemination, and, although many of the cases 
respond to initial chemotherapy following tumour reductive surgery, the majority of 
cases recur and eventually become resistant to chemotherapy (Coleman et al, 2013). 
Therefore, a new strategy for peritoneal dissemination other than conventional 
chemotherapy is urgently needed. 
Immune evasion is an important hallmark of cancer, and a better understanding of 
this mechanism is essential to develop a strong strategy against cancers (Hanahan & 
Weinberg, 2011). In ovarian cancer, multiple inhibitory mechanisms are present, 
including regulatory T cells (Barnett et al, 2010; Curiel et al, 2004), tumour-associated 
macrophages (Zhang et al, 2012), myeloid-derived suppressor cells (MDSCs) (Godoy et 
al, 2013) and inhibitory molecules expressed on tumour cells (Kandalaft et al, 2010; 
Thibodeaux & Curiel, 2011). These players work as strong brakes for anti-tumour 
immunity and obstruct the elimination of cancer by the host immune system (Junttila & 
de Sauvage, 2013). We have attempted to elucidate the inhibitory immune molecules in 
ovarian cancer, such as ULBP2 (NKG2D ligand), COX-1, COX-2, and PD-L1 
(programmed cell death 1 ligand 1, CD274) (Hamanishi et al, 2007; Li et al, 2009; Liu 
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et al, 2009). Among them, PD-L1, a co-inhibitory factor that is expressed on many 
types of cancer cells, showed the closest relation to unfavourable prognosis in ovarian 
cancer (Hamanishi et al, 2011). By binding to its receptor, PD-1 on lymphocytes, 
PD-L1 transmits a signal that inhibits lymphocyte activation (Freeman et al, 2000). 
Efficacy of anti-PD-1 antibodies in multiple cancer types is reported (Topalian et al, 
2012), and clinical trials in ovarian cancer cases are in process. 
IFN-γ is a cytokine that is critical for innate and adaptive immunity. Once 
antigen-specific immunity develops, IFN-γ is secreted by activated effector T cells 
(Dunn et al, 2006). IFN-γ up-regulates MHC class I and class II molecules and 
promotes antigen presentation on tumour cells (Freedman et al, 2000). By these 
functions, IFN-γ was expected to work as an antitumour agent. Nevertheless, in a 
clinical trial, tumour progression was promoted upon administration of IFN-γ to ovarian 
cancer patients (Alberts et al, 2008). The mechanisms of tumour promotion by IFN-γ 
remain unknown.  
IFN-γ is also known to up-regulate PD-L1 expression on tumour cells (Blank et al, 
2004). In mouse melanoma models, IFN-γ secreted from CD8-positive T cells was 
reported to up-regulate PD-L1 (Spranger et al, 2013). Similarly, in mouse ovarian 
cancer peritoneal dissemination models, we have shown that IFN-γ secreted from 
6 
lymphocytes induces PD-L1 on tumour cells (Abiko et al, 2013). However in clinical 
samples of ovarian cancer, especially in peritoneal dissemination, the association 
between PD-L1 expression and IFN-γ has not been clarified so far.  
In the present study, using clinical samples of ovarian cancer including peritoneal 
dissemination, we analyse correlation between CD8-positive lymphocytes and PD-L1 
expression on ovarian cancer cells. Furthermore, relationship between IFN-γ status and 
number of infiltrating lymphocytes is assessed. Then using ovarian cancer mouse 
models, we investigate the role of IFN-γ in the microenvironment of peritoneal 
dissemination. Our findings shed light on the relationship between PD-L1 expression 
and tumour microenvironment, and may provoke a discussion on biomarkers for 
anti-PD-1 therapy. 
 
Materials and Methods 
Microarray datasets of cell lines 
We downloaded a cancer cell line expression dataset from the Cancer Cell Line 
Encyclopedia (CCLE), http://www.broadinstitute.org/ccle (Barretina et al, 2012). It 
consists of 990 cell lines of 24 tissue origins and includes 51 cell lines of ovarian origin. 
Robust Multi-Array Average (RMA) normalisation was performed using R (R: A 
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language and environment for statistical computing, http://www.R-project.org). The cut 




The OV2944-HM-1 (HM-1) mouse ovarian cancer cell line was purchased from 
RIKEN BioResource Center and cultured as previously described (Yamamura et al, 
2012). The ID8 mouse ovarian cancer cell line was kindly provided by Dr. Margit Maria 
Janát-Amsbury (Janat-Amsbury et al, 2006), and were maintained as previously 
described (Abiko et al, 2013). The immortalised human ovarian surface epithelial cell 
line, HOSE1-E7/hTERT (HOSE) was kindly provided by Dr. Hironori Tashiro and was 
maintained as described (Maeda et al, 2005).  
The IFNGR1 (Interferon-γ receptor 1)-depleted cell lines, HM1-shIFNGR1 and 
ID8-shIFNGR1, were generated by lentiviral transfection of short hairpin RNAs 
(shRNA) targeting IFNGR1 using Mouse GIPZ Lentiviral shRNAmir individual 
clone-viral particles (Thermo Scientific; clone ID V2LMM_76619, gene target 
sequence CTAATACTAACCACATAGA). Control cell lines, HM1-control and 
ID8-control, were generated by transfecting a non-silencing, control shRNA (Thermo 
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Scientific; clone ID V12070603). The PD-L1-overexpressing cell line, HM1-pdl1, 
PD-L1-depleted cell line, HM1-Mirpdl1, and the control cell line, HM1-Mircontrol, 
were generated and cultured as previously described (Abiko et al, 2013). 
 
Flow cytometric analysis of PD-L1 expression on tumour cells in patient ascites 
Under the approval of the Institutional Ethical Committee and with written 
informed consent from each patient, ascites from ovarian cancer patients were collected 
during their initial operations. After brief centrifugation, red blood cells were lysed, and 
the remaining cells were washed twice and incubated in RPMI 1640 medium (Nacalai 
Tesque) supplemented with 10% FBS (v/v; Biowest) with or without adding 20 ng/ml 
recombinant human IFN-γ (R&D Systems) to the culture medium for 24 hours prior to 
analysis. At analysis, ascites cells were incubated with fluorescein isothiocyanate 
(FITC)-conjugated anti-EpCAM (epithelial cell adhesion molecule; CD326) antibody 
(clone 9C4; BioLegend) and phycoerythrin (PE)-conjugated anti-PD-L1 antibody 
(cloneMIH1; BD Biosciences) or a matched isotype control (BD Biosciences) at 4ºC for 
30 minutes, washed twice and analysed using a FACSCalibur cytometer (Beckton 
Dickinson) and CellQuest Pro software (Beckton Dickinson). 7-Amino-Actinomycin D 
(AAD) Staining Solution (BD Biosciences) was added 10 minutes prior to analysis to 
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gate out nonviable cells. EpCAM-positive and 7-AAD-negative gated cells were 
analysed as tumour cells, as previously reported (Kitayama et al, 2014). 
 
Immunohistochemistry for ovarian cancer cases 
Under the approval of the Institutional Ethical Committee, written informed 
consent was obtained from the patients, and surgical specimens from 27 ovarian cancer 
cases who underwent an initial operation in Kyoto University Hospital between 1996 
and 2008 were obtained for immunohistochemical analysis. The clinical characteristics 
of the 27 cases are shown in Supplementary Table S1. All 27 cases were advanced 
ovarian cancer cases accompanied by peritoneal dissemination to the omentum or pelvic 
peritoneum. Formalin-fixed, paraffin-embedded blocks from primary ovarian tumours 
and peritoneal disseminated sites were sliced into 4-micrometer-thick sections and used 
for immunohistochemistry.  
Immunohistochemical staining for human PD-L1 was performed as previously 
described (Hamanishi et al, 2007). Two independent gynaecologic pathologists, who 
had no prior information regarding the clinical history of the patients, analysed the 
PD-L1 expression. The samples were evaluated according to the intensity of the staining 
and scored as follows: 0, negative; 1, very weak expression; 2, moderate expression but 
weaker than the positive control; and 3, equivalent to or stronger than the positive 
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control. Placenta was used as a positive control. Samples with heterogeneous staining 
were scored by the intensity of the staining in the largest area. Samples with staining in 
<50% of tumour cells was considered negative. 
Immunohistochemical staining for CD8 (clone C8/144B, Nichirei) and CD4 (clone 
1F6, Nichirei) was performed (Hamanishi et al, 2011; Hamanishi et al, 2007) and 
evaluated as previously described (Barnett et al, 2010). 
 
Microarray profiling of ovarian cancer tissues   
Ovarian cancer specimens were newly obtained from 12 patients, who underwent 
primary surgery for ovarian cancer at Kyoto University Hospital between 2010 and 
2013 and served for microarray analysis. These microarray data (deposited in NCBI’s 
Gene Expression Omnibus, accession number GSE55512, 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE55512) were added to 63 
patients’ data from our previously reported dataset of 64 ovarian cancer patients, 
KOV-MA-64 (GEO accession GSE 39204) (Abiko et al, 2013), and termed KOV-75. 
One case in KOV-MA-64 was excluded because we could not obtain slides for 
immunohistochemistry. The patient characteristics of KOV-75 are listed in 
Supplementary Table S2.  
11 
HOSE cells were incubated in 8 separate culture dishes, 4 dishes with and 4 dishes 
without 500 IU/ml recombinant human IFN-γ (R&D Systems) in the culture medium 
for 6 hours prior to the analysis. The cells were then harvested, and total RNA was 
extracted using the RNAeasy Kit (Qiagen) and analysed using the Human Genome 
U133 Plus 2.0 Array (Affymetrix). The results were deposited in Gene Expression 
Omnibus, and are accessible through GEO series accession number GSE55510 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE55510).  A student t-test was 
performed between the IFN-γ-added and IFN-γ-free groups, and probes showing an 
expression value greater than 5.0 in at least one of the samples, a fold change of over 2 
and a p value <0.001 were selected as “IFN-γ signature genes (295 probes)”. A publicly 
accessible microarray dataset of IFN-treated cells (GEO accession GSE3920) was 
downloaded (Indraccolo et al, 2007). Single sample gene set enrichment analysis 
(ssGSEA) (Barbie et al, 2009) for “IFN-γ signature” in GSE3920 and KOV-75 was 
performed using R, as previously reported (Kawasaki et al, 2014). Briefly, R code for 
ssGSEA was downloaded from Genepattern 
(http://www.broadinstitute.org/cancer/software/genepattern/), and gmt file for IFN-γ 
signature gene symbols and gct file for KOV75 were used as input files and 




Female B6C3F1 and C57BL/6 mice were purchased from CLEA Japan. All animal 
experiments were approved by the Kyoto University Animal Research Committee, and 
animals were maintained under specific pathogen-free conditions. To evaluate the effect 
of IFNGR1 on the survival and progression of peritoneal dissemination, HM-1 cells 
(1x106) were injected into the abdominal cavities of syngeneic mice. Mice were 
euthanised before reaching the moribund state. To evaluate the effect of IFN-γ on 
tumour growth, HM-1(1x106) or ID8 cells ((5x106) were injected subcutaneously into 
the right flanks of syngeneic mice, tumour size was calculated every other day, and the 
volume of the tumour was estimated using the following formula; 
Estimated tumour volume=(r1 x r2 x r3) /2. 
 
Immunohistochemistry for mouse tumours 
Mouse tumour cryosections (10-micrometer thick) were fixed on a glass slide with 
acetone and stained with an anti-CD4 (clone H129.19; BD Pharmingen) or anti-CD8 
antibody (clone KT15; SeroTec), as previously described (Hamanishi et al, 2010). 
Anti-mouse-PD-L1 antibody (R & D Systems) was used according to the same protocol. 
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Western blotting analysis of mouse tumours 
    Tumor tissue was lysed in RIPA buffer with a protease inhibitor cocktail (EMD) 
and a phosphatase inhibitor cocktail (Nacalai Tesque). Protein was separated by 
SDS-PAGE gel and immunoblotted with anti-mouse-PD-L1 antibody (R & D Systems) 
or anti-GAPDH antibody (Abcam). Specific proteins were visualized using ECL Plus 
Western Blotting Reagent (GE Healthcare Life Sciences). 
 
Flow cytometric analysis for mouse cell line 
Cultured cells were harvested and incubated with a FITC-conjugated antibody 
against mouse IFNGR1 (clone 2E2, eBioscience) or a matched isotype control 
(eBioscience) at 4ºC for 30 minutes, washed twice and analysed as described above. 
 
Flow cytometric analysis of tumour-infiltrating lymphocytes in mice 
Mice with tumour formations were sacrificed, and the tumours were collected. 
After straining through a 70-micrometer cell strainer (BD Biosciences), the tumour cells 
were washed twice and incubated with a PerCP-conjugated anti-mouse CD3e antibody 
(BD Biosciences), FITC-conjugated anti-mouse CD4 antibody (BD Biosciences), Alexa 
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Fluor 647-conjugated anti-mouse CD8a antibody (BD Biosciences) or matched isotype 
controls. For analysis for MDSCs, cells were stained with PerCP-conjugated anti-mouse 
Gr-1 antibody (BD Biosciences) and APC-conjugated anti-mouse CD11b antibody (BD 




A paired t-test and student t-test were used for the immunohistochemistry analysis 
of human samples and mice tumours. Survival was analysed using the Kaplan-Meier 
survival analysis with the log-rank test using the GraphPad Prism 5 software. The one 
way ANOVA test was used to analyse tumour volume in mouse subcutaneous tumours. 
A P value less than 0.05 was considered significant. 
 
Results 
The majority of unstimulated ovarian cancer cell lines does not express PD-L1, but 
does express IFN-γ receptors 
The expression of PD-L1 mRNA in the CCLE dataset of 990 cell lines was 
evaluated. As shown in Figure 1A, the average PD-L1 expression levels were relatively 
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low in 51 ovarian cancer cell lines when compared with the cell lines of other origins. 
Only 16 of 51 ovarian cancer cell lines (31%) were PD-L1-positive, while 411 of 939 
cell lines of other origins (44%) were PD-L1 positive. 
However, we have reported that PD-L1 protein expression in ovarian cancer is 
positive in 68-69% of the cases using immunohistochemistry (Abiko et al, 2013; 
Hamanishi et al, 2007). As IFN-γ induced PD-L1 in many types of ovarian cancer cell 
lines (Abiko et al, 2013), we hypothesised that PD-L1 in ovarian cancer cells in patients 
is not expressed constitutively, but expressed transiently in response to IFN-γ in the 
tumour microenvironment. The IFN-γ receptor is a heterodimer that consists of two 
chains: IFNGR1 and IFNGR2. As it is reported that some ovarian cancer cells lack 
protein expression of IFNGR1 (Duncan et al, 2007), we then evaluated the expression 
of IFNGR1 and IFNGR2 mRNA in the same dataset. As shown in Figure 1B, all 51 
ovarian cancer cell lines expressed IFNGR1 and IFNGR2. Thus, the majority of ovarian 
cancer cell lines does not express PD-L1 without induction, but does express two 
subunits of the IFN-γ receptor. 
 
IFN-γ induces PD-L1 on ovarian cancer cells 
It is known that IFN-γ induces PD-L1 on many cell types in vitro (Muhlbauer et al, 
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2006; Waeckerle-Men et al, 2007) including ovarian cancer cell lines (Abiko et al, 
2013). To show that IFN-γ can also induce PD-L1 on tumour cells in ovarian cancer 
patients, we performed flow cytometric assays on ovarian cancer patient ascites cells. 
Two of 4 analysed cases were positive for PD-L1 expression on tumour cells (Figure 
1C). When cells from the PD-L1-negative case (*) were incubated with IFN-γ, the 
PD-L1 expression on tumour cells was markedly induced (Figure 1D). 
 
The IFN-γ signature score is high in samples with high CD4- and CD8-positive 
lymphocyte infiltration  
To analyse the IFN-γ status in ovarian cancer clinical samples and because 
immunohistochemistry for IFN-γ is technically difficult, we generated an IFN-γ 
signature using microarray data to evaluate the amount of IFN-γ in each case. A set of 
295 probes targeting 194 known gene and 17 unknown gene sites were significantly 
up-regulated by IFN-γ and was named the “IFN-γ signature” (Supplementary Table S3). 
To validate the IFN-γ signature, we applied this signature using ss-GSEA to a publicly 
accessible gene dataset, GSE3920, and found that IFN-γ signature score was high in 
IFN-treated cells (Supplementary Figure S1). 
We then applied IFN-γ signature to KOV-75 microarray data, which included 75 
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ovarian cancer clinical samples, by means of ss-GSEA and obtained IFNγ signature 
score for each sample. Immunohistochemistry for CD4 and CD8 was performed, and 
the CD4-positive and CD8-positive cell number was counted (Supplementary Figure 
S2A, Supplementary Table S4). Strikingly, the IFN-γ signature score was strongly 
correlated to the number of infiltrating CD8- or CD4-positive lymphocytes, or the sum 
of them (P<0.0001, P=0.0011, P<0.0001, respectively, Figure 2A-C). These data 
suggest that the IFN-γ in the ovarian cancer microenvironment is derived from 
lymphocytes, and an IFN-γ-rich microenvironment is strongly correlated to a 
lymphocyte-rich microenvironment. 
 
The stromal CD8-positive cell number is high in peritoneally disseminated ovarian 
cancer and is correlated with PD-L1 expression 
Immunohistochemical analysis for CD8 was performed in paired surgical 
specimens of primary ovarian tumour and peritoneal dissemination from 27 ovarian 
cancer cases. In both primary ovarian and peritoneally disseminated tumours, 
CD8-positive cell numbers tended to be higher in the cancer stroma than in the tumour 
epithelium (P=0.09, P=0.0001, respectively, Supplementary Figure S2B, Figure3A). 
Furthermore, the number of CD8-positive cells in the cancer stroma was significantly 
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high in the peritoneal dissemination samples compared to the primary ovarian tumour 
samples (P=0.004, Supplementary Figure S2C), while the CD8-positive cell number in 
the cancer epithelium was not significantly different between the peritoneal 
dissemination and primary ovarian tumour samples (Supplementary Figure S2D).  
When serial sections from peritoneal disseminations were stained with the 
anti-PD-L1 antibodies (Figure 3B), the CD8-positive cell number in the stroma were 
strongly correlated to PD-L1 expression (PD-L1 staining score 0-1 vs 2-3, P<0.001, 
Figure 3C, Supplementary Figure S2E).  
 
Subcutaneous or peritoneal mouse tumours show different levels of PD-L1 expression 
and lymphocyte infiltration 
As CD8-positive lymphocytes are reported to be the source of IFN-γ in cancer 
microenvironment (Kooi et al, 1993; Taube et al, 2012), we next attempted to 
investigate the relationship between PD-L1 expression on tumour cells and the tumour 
microenvironment by using two types of mouse models, focusing on IFN-γ in the 
tumour microenvironment. The mouse ovarian cancer cell line, HM-1, forms 
subcutaneous tumours or peritoneally disseminated tumours after injection into 
syngeneic immune-competent B6C3F1 mice. Peritoneally disseminated tumour cells 
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strongly expressed PD-L1, while subcutaneous tumours showed low PD-L1 expression 
(Figure 4A). Tumour-infiltrating CD8-positive cells were scarce in subcutaneous 
tumours, while they were prominent in peritoneally disseminated tumours (P=0.045, 
Figure 4B). Strong infiltration of CD8-positive cells in peritoneally disseminated 
tumours was also confirmed using flow cytometry (P=0.011, Figure 4C). Though the 
difference in CD4-positive cell count between subcutaneous and peritoneally 
disseminated tumours did not reach statistical significance using immunohistochemistry 
(Figure 4D), flow cytometric analysis showed significant difference between the two 
groups (P=0.026, Figure 4E). 
 
IFN-γ signal blockade in tumour cells resulted in lower PD-L1 expression and longer 
mouse survival in a mouse peritoneal dissemination model 
To examine the effects of IFN-γ on tumour cells, we established an IFNGR1 
(Interferon-gamma Receptor 1) knockdown cell line, HM1-shIFNGR1, using shRNA. 
Stable depletion of the IFNGR1 protein was confirmed using flow cytometry (Figure 
5A). After injection into the mouse peritoneal cavity, both HM1-shIFNGR1 and 
HM1-control formed peritoneally disseminated tumours, but the expression of PD-L1 
was weaker in HM1-shIFNGR1 cells (Figure 5B, C). Number of tumour-infiltrating 
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CD8-positive lymphocytes was significantly larger in HM1-shIFNGR1 group (Figure 
5D). Dissemination occurred earlier and was prominent in the HM1-control group on 
day 19, while it was macroscopically invisible in the HM1-shIFNGR1 group (Figure 
6A). Mouse survival was significantly longer in the HM1-shIFNGR1 group (P=0.021, 
Figure 6B), which indicated that the IFN-γ signal associated with PD-L1 up-regulation 
accelerated tumour progression of ovarian cancer cells in the peritoneal cavity. 
 
IFN-γ induces PD-L1 expression on tumour cells and facilitates tumour growth in a 
mouse subcutaneous model 
To further examine the effects of IFN-γ on tumour cells, we administered IFN-γ to 
subcutaneous tumours in the mice using two previously established cell lines, 
HM1-Mirpdl1 (PD-L1-depleted HM-1) or HM1-Mircontrol. The protocol scheme is 
shown in Supplementary Figure S3A. PD-L1 expression was induced by IFN-γ 
(Supplementary Figure S3B) and tumour growth was significantly accelerated by IFN-γ 
in HM1-Mircontrol subcutaneous tumours (P<0.05, Supplementary Figure S3C). On the 
other hand, HM1-Mirpdl1 IFN-γ-injected tumours showed growth that was similar to 
that of PBS-injected tumours, indicating that tumour growth caused by IFN-γ was 
completely abrogated by knockdown of PD-L1 (Supplementary Figure S3C). We 
21 
repeated this procedure in another mouse cell line, ID8. Although the ID8 subcutaneous 
tumours were smaller and the difference between groups did not reach statistical 
significance, the results showed the same tendency, with the ID8-control with IFN-γ 
administration presenting the largest tumour size (Supplementary Figure S3D). 
 
PD-L1 attenuates CD8+ lymphocytes infiltration into the tumour 
To investigate the effect of PD-L1 on host immunity, we compared the 
tumour-infiltrationg immune cells in peritoneal disseminated tumour of HM1-pdl1 
(PD-L1-overexpressing HM-1) and in that of HM1-Mirpdl1. As shown in 
Supplementary Figure S4A, number of CD8+ (-positive) tumour-infiltrating 
lymphocytes (TILs) was significantly larger in HM1-Mirpdl1, indicating that PD-L1 
reduces the absolute number of infiltration of the CD8+ TILs. On the other hand, 
number of CD4+ TILs and myeloid derived suppressor cells (MDSCs) was similar in 
both groups (Supplementary Figure S4B, C). 
 
Discussion 
We previously reported that PD-L1 expression is positive in nearly 70% of ovarian 
cancer cases (Hamanishi et al, 2007), and is significantly related to positive malignant 
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cells in ascites and unfavourable prognosis (Abiko et al, 2013). We also reported that 
PD-L1 can be induced by IFN-γ secreted from CTLs in mouse models (Abiko et al, 
2013). Though PD-L1 was not expressed in most of the ovarian cancer cell lines, 
ovarian cancer cells in patient ascites expressed PD-L1 in response to IFN-γ, and the 
IFN-γ signature score was closely related to lymphocyte infiltration into the tumour in 
clinical samples (Figure 1). These results are compatible with the report in melanoma 
(Spranger et al, 2013; Taube et al, 2012), which indicates that IFN-γ derived from 
CD8-positive T lymphocytes induces PD-L1 in vivo. 
It was reported that a high number of intraepithelial CTLs in ovarian cancer is 
associated with favourable prognosis (Hwang et al, 2012), but few reports concerning 
the stromal CTL number have been published. Here we reported for the first time that, 
the number of CTLs in cancer stroma was very high in peritoneal dissemination, and 
was strongly correlated to PD-L1 expression in peritoneally disseminated tumour cells 
(Figure 2). Abundant lymphocytes are originally present in the omentum, and they may 
eventually distribute into the stroma of disseminated tumours. Interestingly, 
intraepithelial CTL number was low in both primary tumour and peritoneal 
dissemination (Supplementary Figure S2E). Since PD-L1 on tumour cells decreases 
CD8+ lymphocyte infiltration (Supplementary Figure S4A), PD-L1 on tumour cells, 
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induced by IFN-γ from CTLs, may expel CTLs from the tumour epithelium to the 
stroma especially in peritoneal dissemination. Although PD-L1 is known to suppress 
cytotoxic activity of CTLs (Abiko et al, 2013; Hirano et al, 2005; Iwai et al, 2002), 
function of TILs was similar regardless of different expression status of PD-L1 on 
tumour cells (data not shown) probably because TIL function is inevitably suppressed 
by various mechanisms other than PD-L1 expression (Curiel et al, 2004; Gabrilovich & 
Nagaraj, 2009; Lob et al, 2009; Walunas et al, 1996). 
The biological function of IFN-γ includes increasing antigen presentation and 
promoting Th1 differentiation, leading to cellular immunity (Dunn et al, 2006). 
Therefore, IFN-γ has been expected to possess anti-tumour effects in cancer patients. 
Nevertheless, upon administration of IFN-γ to ovarian cancer patients, the opposite 
results were observed in two phase-III clinical trials (Alberts et al, 2008; Windbichler et 
al, 2000); tumour progression was promoted when IFN-γ was combined with standard 
chemotherapy (Alberts et al, 2008). Recent studies have shown that IFN-γ seems to 
have two faces, one good and one bad: immunoactivating/immunoregulatory and 
anti-tumour/tumour-promoting (Zaidi & Merlino, 2011). One indirect 
tumour-promoting mechanism of IFN-γ was described as the tumour-immunoediting 
theory (Dunn et al, 2002; Dunn et al, 2006), in which IFN-γ works through selective 
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pressure and forces the evolution of tumour cells to IFN-γ-resistant phenotypes. 
However, no direct mechanism to explain the tumour-promoting effect of IFN-γ was 
identified. To explain the tumour-promoting effect of IFN-γ, we hypothesised that 
induction of PD-L1 by IFN-γ overwhelms the anti-tumour effects of IFN-γ. To prove 
our hypothesis, we conducted animal experiments to describe tumours grown in 
different microenvironment. The subcutaneous model refers to a tumour grown in a 
microenvironment with a smaller number of CTL infiltration; and the peritoneal 
dissemination model refers to a microenvironment with a larger amount of CTL 
infiltration, as is the case in many cases of human ovarian cancer peritoneal 
dissemination. IFN-γ signal inhibition resulted in lower PD-L1 expression in the tumour 
cells and prolonged survival in the peritoneal dissemination model (Figure 5, 6). IFN-γ 
administration resulted in higher PD-L1 expression in the tumour cells and the 
acceleration of tumour progression in the subcutaneous model (Supplementary Figure 
S3). PD-L1 knockdown in tumour cells abrogated the tumour-promoting effect of IFN-γ 
(Supplementary Figure S3C). These data indicate that IFN-γ promotes tumour growth 
by inducing PD-L1 in the tumour.  
The anti-PD-1 antibody, Nivolumab, shows striking effects in melanoma, lung and 
renal cancers (Topalian et al, 2012). In our ongoing clinical trial for ovarian cancer, we 
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have also found that some patients strikingly respond to Nivolumab but others do not 
(Hamanishi et al, unpublished data). In 2012, a report suggesting that the predictive 
biomarker for anti-PD-1 therapy was PD-L1 expression in the tumour won attention 
(Topalian et al, 2012). However, upon further investigation, conflicting reports followed, 
and now the issue is controversial (Wolchok et al, 2013). Our data in this study imply 
that PD-L1 expression on ovarian cancer cells can be altered by its microenvironment. 
Therefore, verifying PD-L1 expression on a single slide from one single biopsy site may 
not represent the immune microenvironment of the entire tumour and, thus, may not be 
sufficient for predicting the efficacy of Nivolumab in the entire patient. Instead, 
indicators such as IFN-γ signature or lymphocyte infiltration, which reflect the IFN-γ 
status in the tumour microenvironment may serve as potential biomarkers. Further 
investigation regarding these markers and response to anti-PD-1 therapy in clinical trial 
is required. 
In conclusion, stromal CTLs in ovarian cancer peritoneal dissemination are 
strongly affecting anti-tumour immunity through PD-L1 expression. IFN-γ from stromal 
CTLs induces PD-L1 and promotes tumour progression in ovarian cancer 
microenvironment. Our results indicate that PD-L1 expression on ovarian cancer cells 
varies according to the microenvironment. Lymphocyte infiltration and the IFN-γ status 
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may be the keys for effective immunotherapy, including anti-PD-1 therapy.  
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Titles and Legends to Figures 
Figure 1. PD-L1 expression on ovarian cancer cells is induced by IFN-γ. 
A, PD-L1 expression in cell lines from the CCLE dataset. The horizontal line at 
value 4.950718 represents the determined cut off value, as mentioned in the materials 
and methods section. 
B, Expression of IFNGR1 and IFNGR2 in cell lines of ovarian origin from the 
CCLE dataset. The horizontal and vertical lines represent the determined cut off values. 
C, PD-L1 expression in ascites tumour cells from four cases of ovarian cancer. 
CD326-positive and 7-AAD-negative cells were gated as viable tumour cells. Open 
histogram with grey line; anti-PD-L1 antibody, filled histogram; isotype control. 
PD-L1-positive cases (lower panels) and negative cases (upper panels) are shown. 
D, Ascites cells designated by * in Figure 1C were incubated with (upper panel) or 
without (lower panel) IFN-γ for 24 hours, and PD-L1 expression is shown. Open 
histogram with grey line; anti-PD-L1 antibody, filled histogram; isotype control. 
 
Figure 2. IFN-γ signature score is correlated to lymphocyte infiltration in ovarian 
cancer clinical samples.  
The IFN-γ signature score (x-axis) and number of CD8-positive (A), CD4-positive 
41 
(B), or both (C), lymphocytes (y-axis) showed a significant, positive correlation in 
KOV75 cases. 
 
Figure 3. Stromal CD8-positive cells are prominent in peritoneal dissemination and 
are related to PD-L1 expression on tumour cells in ovarian cancer clinical samples. 
A, Number of intraepithelial and stromal CD8-positive cells in peritoneal 
dissemination. 
B, Immunohistochemistry for PD-L1 and CD8. Representative cases are shown. 
The area marked “E” represents tumour epithelium, and the area marked “S” represents 
tumour stroma. Note the abundant stromal infiltration of CD8-positive cells, and dense 
PD-L1 staining on both cancer cells and immune cells. Bars; 50μm. 
C, PD-L1 expression level and stromal CD8-positive cell number in a peritoneal 
dissemination sample. PD-L1 staining score 0-1 vs. 2-3, P<0.001. 
 
Figure 4. PD-L1 expression and lymphocyte infiltration vary between mouse 
subcutaneous and peritoneal tumours. 
A, Representative images of immunohistochemistry for PD-L1 and CD8 for 
subcutaneous and peritoneal disseminated tumours of HM-1. Green bars; 25μm, black 
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bars; 50μm. 
B, CD8-positive cell number per high-power field using immunohistochemistry 
(n=3).  
C, The percentage of CD8-positive cells in the total cells of tumour tissue analysed 
by flow cytometry (n=4).  
D, CD4-positive cell number per high-power field using immunohistochemistry 
(n=3). 
E, The percentage of CD4-positive cells in the total cells in tumour tissue analysed 
using flow cytometry (n=4). 
 
Figure 5. Blocking the IFN-γ signal in the mouse peritoneal dissemination model 
resulted in lower PD-L1 expression and more TILs. 
A, IFNGR1 expression on HM-1 cells was successfully depleted by shRNA. 
HM1-control (black line histogram), HM1-shIFNGR1 (blue line histogram) and 
matched isotype control (shaded histogram). 
B, Upper panels; Immunohistochemistry for PD-L1 in mouse peritoneal 
disseminated tumours. Green bars; 25μm. Lower panels; Expression of PD-L1 on 
tumour cells. Green line histogram; anti-PD-L1 antibody, filled histogram; isotype 
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control. Representative data from 4 mice per group with similar results. 
C, Western blotting analysis for mouse peritoneally disseminated tumours. Cont; 
HM1-control, sh; HM1-shIFNGR1. 
D, CD8-positive cells in mouse peritoneally disseminated tumour. Upper panel; 
representative dot plots. The percentage of CD3-positive, CD8-positive cells in total 
tumour cells are shown in the box. Lower panel; bar graph, n=4.  
 
Figure 6. Blocking the IFN-γ signal in the mouse peritoneal dissemination model 
resulted in slower tumour progression and longer survival. 
A, Photograph of mouse peritoneum from HM1-control- or HM1-shIFNGR1 
injected group on day 19. Yellow arrow heads: peritoneally disseminated tumours on 
peritoneum, blue arrow heads: disseminated tumours on omentum. 
B, Survival of HM1-shIFNGR1-injected mice (blue line) and 
HM1-control-injected mice (green line) (n=6). 
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